Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer

二维码有效期 120s

摘要In recent years, lung cancer has been the most commonly diagnosed cancer globally; 1.6 million people died of lung cancer in 2012 globally, making lung cancer the leading cause of cancer-related deaths.1,2 Lung cancer can be mainly histologically classified into two types: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), ac-counting for approximately 85% and 15% of cases, respectively.3 NSCLC can be further classified as squamous cell carcinoma, adenocarcinoma, and large-cell lung carcinoma, among which lung adenocarci-noma is the most common primary malignant tumor. Unfortunately, most NSCLC cases are diagnosed at a late stage when the survival rate is low; the 5-year survival rate is approximately 16%.

作者单位 Department of Clinical Medicine, The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210029, China ^[1] Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China ^[2]

关键词 Next-generation sequencing Non-small-cell lung cancer Diagnosis Therapy Drug resistance

栏目名称 Editorial

DOI 10.1016/j.cdtm.2017.02.009

发布时间 2017-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交